In NZB/W and MRL-lpr lupus-like mouse models, CART cells targeting CD19 successfully eliminated aberrant CD19+ B cells and induced remission with decline in total IgM and IgG antibodies as well as anti-DNA IgG and IgM. The gene discussed is CD19; the disease is systemic lupus erythematosus.